Voloridge Investment Management
BCRX icon

Voloridge Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Voloridge Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-449,743
Closed -$3.51M – 1015
2025
Q4 		$3.51M Sell
449,743
-507,278
-53% -$3.67M 0.01% 826
2025
Q3 		$7.26M Sell
957,021
-1,517,054
-61% -$12.6M 0.02% 634
2025
Q2 		$22.2M Buy
2,474,075
+440,292
+22% +$4.1M 0.08% 298
2025
Q1 		$15.3M Buy
2,033,783
+453,823
+29% +$3.66M 0.06% 434
2024
Q4 		$11.9M Sell
1,579,960
-212,948
-12% -$1.62M 0.04% 526
2024
Q3 		$13.6M Sell
1,792,908
-797,953
-31% -$6.07M 0.05% 483
2024
Q2 		$16M Buy
2,590,861
+1,623,139
+168% +$8.96M 0.06% 446
2024
Q1 		$4.92M Sell
967,722
-113,924
-11% -$641K 0.02% 665
2023
Q4 		$6.48M Buy
1,081,646
+737,798
+215% +$4.28M 0.03% 566
2023
Q3 		$2.43M Buy
343,848
+252,451
+276% +$1.81M 0.01% 867
2023
Q2 		$643K Sell
91,397
-581,868
-86% -$4.67M ﹤0.01% 1196
2023
Q1 		$5.62M Buy
673,265
+408,048
+154% +$3.93M 0.03% 639
2022
Q4 		$3.04M Buy
+265,217
New +$3.31M 0.02% 844
2022
Q2 		– Sell
-127,510
Closed -$2.07M – 1424
2022
Q1 		$2.07M Sell
127,510
-566,320
-82% -$9.08M 0.01% 936
2021
Q4 		$9.61M Sell
693,830
-486,467
-41% -$6.44M 0.05% 485
2021
Q3 		$17M Buy
1,180,297
+607,919
+106% +$9.59M 0.11% 253
2021
Q2 		$9.05M Buy
+572,378
New +$7.78M 0.06% 439
2021
Q1 		– Sell
-1,038,874
Closed -$7.74M – 1393
2020
Q4 		$7.74M Buy
+1,038,874
New +$5.36M 0.06% 348
2019
Q4 		– Sell
-35,646
Closed -$102K – 1085
2019
Q3 		$102K Sell
35,646
-94,654
-73% -$294K ﹤0.01% 1016
2019
Q2 		$494K Buy
130,300
+117,795
+942% +$709K 0.01% 566
2019
Q1 		$102K Buy
+12,505
New +$107K ﹤0.01% 908

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Voloridge Investment Management's BCRX Position: Q1 2026 in Review

Voloridge Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 449,743 shares — an estimated $3.51M sold.

Voloridge Investment Management first reported a position in BCRX in Q1 2019 and held it in 21 quarters. The position peaked at $22.2M in Q2 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Voloridge Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Voloridge Investment Management sold 449,743 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $3.51M.
  • Voloridge Investment Management first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 21 quarters.
  • Voloridge Investment Management's BioCryst Pharmaceuticals position peaked at $22.2M in Q2 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Voloridge Investment Management's 13F filing for Q1 2026, filed 15 May 2026.